Skip to main content

Table 1 Biologics currently in development or approved for the treatment of asthma

From: Severe asthma and quality of life

Drug Target Biomarkers Effects Route/Dose
Omalizumab IgE Ag-specific IgE
Better responses with higher FeNO and blood eosinophils >300 cells/ uL
Decreased asthma exacerbations 150–375 mg SC q2-q4wks; frequency based on IgE and body weight
Mepolizumab IL-5 Blood eosinophil count >150 cells/uL at initiation or 300 cells/uL in past year Decreased asthma exacerbations; Improvement in FEV1 100 mg SC q4wk.
Reslizumab IL-5 Blood eosinophil count >400 cells/uL Decreased asthma exacerbations; Improvement in FEV1 3 mg/kg IV q4wks
Benralizumab IL-5Rα Blood eosinophil count >300 cells/ uL Decreased asthma exacerbations; Improvement in FEV1. 30 mg SC q4wks ×3 then q8wks
Tralokinumab IL-13 Elevated blood periostin and DDP-4 Improvement in FEV1 Not Defined
Dupilumab IL-4Rα Better responses with blood eosinophil count >300 cells/ uL Decreased asthma exacerbations;
Improvement in FEV1
200 or 300 mg SC q2wks; administered at home
  1. DDP-4 dipeptidyl peptidase-4, FeNo fractional excretion of nitric oxide, FEV1 forced expiratory volume in 1 s